Form 8-K - Current report:
SEC Accession No. 0001628280-25-009967
Filing Date
2025-03-04
Accepted
2025-03-04 17:09:59
Documents
15
Period of Report
2025-03-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20250304.htm   iXBRL 8-K 28553
2 EX-99.1 a2024q4ex991earningsrelease.htm EX-99.1 245278
6 GRAPHIC image_0.jpg GRAPHIC 24016
  Complete submission text file 0001628280-25-009967.txt   454483

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20250304.xsd EX-101.SCH 1894
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20250304_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20250304_pre.xml EX-101.PRE 12611
17 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20250304_htm.xml XML 2723
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 25706189
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)